Medication evidence profile
Disopyramide
Clinical overview
Disopyramide has public medication-list entries in JARS 2025, Yamada-ABS 2023, and CALS 2022 Table 4. These are 3 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | 2 |
| Yamada-ABS | 3 |
| BAAS | Not listed |
| Swe-ABS | Not listed |
| GABS | Not listed |
| KABS | Not listed |
| CALS | 1 |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
How to interpret the evidence
3 of 7 public source versions contain an explicit medication-list entry for disopyramide.
The recorded values differ across the source rows for disopyramide. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.
None of the public rows in this profile is an explicit zero. An unlisted source still supplies no value.
Source labels and provenance · 3 observations
- Japanese Anticholinergic Risk Scale (JARS) 2025 English translation
Source label: Disopyramide. Published value: 2.
Source version: JARS-2025
Source location: RC4 source recovery; recovery_scope=primary_table_complete; ATC=C01BA03
Observation: JARS_2025_R0075; rating state: published_rating. - Yamada Pharmacological Anticholinergic Burden Scale 2023
Source label: Disopyramide. Published value: 3.
Source version: YAMADA-ABS-2023
Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
Observation: YAMADA_ABS_2023_R0064; rating state: published_rating. - CALS 2022 - primary final Table 4
Source label: Disopyramide. Published value: 1.
Source version: CALS-2022-primary-table4
Source location: Table 4; literal capture row 72; displayed table row 11; displayed column 2
Observation: CALS2022_T4_0072; rating state: published_final_table_rating.
What this page does not establish
- No medication-list entry is available here from BAAS 2019, Swe-ABS 2023, GABS 2018, and KABS 2020 open validation supplement. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- No route inference unless present in the source label.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Mizokami F, Mizuno T, Taguchi R, et al. Development of the Japanese Anticholinergic Risk Scale: English translation of the Japanese article. Geriatr Gerontol Int. 2025;25(1):5-13. doi:10.1111/ggi.15001. Open source
- Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
- Ramos H, Moreno L, Pérez-Tur J, Cháfer-Pericás C, García-Lluch G, Pardo J. CRIDECO Anticholinergic Load Scale: an updated anticholinergic burden scale. Comparison with the ACB Scale in Spanish individuals with subjective memory complaints. J Pers Med. 2022;12(2):207. doi:10.3390/jpm12020207. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Disopyramide
Ask about this medication